Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering

Reliable Detection of SGLT2 Protein by Knockout-Based Antibody Characterization

BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) mediates renal glucose reabsorption, and its pharmacological inhibition exerts cardio-and renoprotective benefits. Despite widespread clinical interest, reliable detection of SGLT2 protein remains challenging due to concerns regarding antibody specificity. METHODS: Eight commercially available anti-SGLT2 antibodies were evaluated by immunohistochemistry and Western blotting using kidneys and hearts from genetically engineered Sglt2-deficient mice and rats. Human kidney tissues, including renal cell carcinoma samples, were also examined. RESULTS: Among the antibodies tested, ab306558 and HPA041603 showed specific immunostaining in rodent kidneys, with minimal background in wild-type tissues and complete absence of staining in Sglt2-deficient samples. However, ab306558 was unsuitable for human samples because of nonspecific staining.

The World in 100 Years FULL EPISODE | Science Fiction Documentary

What will the world really look like in 100 years?

Forget flying cars, impossible megacities, and science-fiction fantasies. This documentary explores a realistic vision of life in the year 2,126 based on current trends in artificial intelligence, climate adaptation, biotechnology, energy, space exploration, economics, and human evolution.

How will cities change as the planet warms? What happens when AI becomes part of everyday life? Will humans live to 120 years? Will neural implants blur the line between biology and technology? Could Mars become a permanent home for thousands of people? And what happens to society when work, truth, privacy, and even human identity are redefined?

Travel one century into the future and discover a world that is both familiar and radically different from our own. A world shaped by the choices humanity is making right now.

From climate-engineered cities and fusion-powered civilizations to Martian settlements, artificial intelligence, genetic medicine, digital consciousness, and the search for life beyond Earth, this is a deep exploration of the most plausible future awaiting our species.

The future isn’t written.

Continue reading “The World in 100 Years FULL EPISODE | Science Fiction Documentary” | >

The Technology That Will Change Humans Forever

For extra nuances and all the references, please see the newsletter: https://staycuriousmetabolism.substack.com/p/can-we-become-l…a?r=40ekz2… StayCurious Human Enhancement Series.

The StayCurious Human Enhancement Series.

We’re launching a new series at StayCurious Metabolism called Peptides Plus, where we’ll explore the most promising tools available today—and the innovations that may shape tomorrow. We have dozens of deep dives planned, covering everything from emerging therapeutics to cutting-edge performance and longevity interventions.

GO HERE: https://staycuriousmetabolism.substac…

Chapters.
0:00 — Superhuman Biology Is Already Starting.
2:40 — Beyond GLP-1: Fat Loss Without Muscle Loss.
7:28 — Gene Editing, CRISPR, and the Future of Disease Cure.
14:57 — Cellular Reprogramming and Biological Age Reset.
18:49 — MicroRNAs, Mitochondria, and What Comes Next.

Video Description.

Continue reading “The Technology That Will Change Humans Forever” | >

Silver nanoparticles pave the way for precise DNA cutting and joining

DNA is composed of long chains that act as the blueprint for living organisms. In genetic engineering, scientists cut DNA at specific sites and join the resulting fragments to other DNA sequences, enabling applications such as advanced crop breeding, treatment of genetic diseases, and the generation of animal models for drug discovery.

Assembling short DNA fragments requires overhanging sequences, known as sticky ends, to facilitate efficient binding. However, generating sticky ends requires precise cutting at targeted sites, which remains challenging with current technologies.

A Japanese research group has developed a silver nanoparticle-based technology to precisely cut and join DNA at targeted sites, achieving two to five times higher DNA assembly efficiency than conventional restriction enzyme methods. These findings were published in the journal Nucleic Acids Research.

Strategies to boost antibody selectivity in oncology

Antibodies in oncology are being equipped with toxic cargoes and effector functions that can kill cells at very low concentrations. A key challenge is that most targets on cancer cells are also present on at least some healthy cells. Shared targets can result in off-tumor binding and compromise the safety and potential of therapeutic candidates. In this review, we survey strategies that can help direct biologics to cancer sites more selectively. These strategies are becoming increasingly feasible thanks to advances in molecular design and engineering. The objective is to create therapeutics that exploit changes in cancer and leverage the human body infrastructure, enabling therapeutics that discriminate not just self from non-self but diseased from healthy tissue.

Novel synthetic biomolecule degrades disease-related proteins

Northwestern Medicine scientists have developed a novel synthetic biomolecular condensate that can degrade intracellular disease-causing proteins, providing a framework for new therapeutic approaches for a wide range of diseases, as detailed in a recent study published in Nature Communications.

Shana Kelley, Ph.D., the Neena B. Schwartz Professor of Chemistry, Biomedical Engineering, and Biochemistry and Molecular Genetics and the president of the Chan Zuckerberg Biohub Chicago, was senior author of the study.

Targeted protein degradation is an emerging therapeutic strategy that harnesses cells’ own degradation machinery to clear disease-causing proteins. However, achieving this degradation process across different cell types has remained a challenge due to subtle variations in protein structure.

Munk Debate on Gene Editing

On April 21, the Munk Debates convened a special debate about gene editing in Deerfield, Massachusetts for 650 students at Deerfield Academy.

Motion: Be it Resolved, let’s engineer better human beings.

About the Debate:
New powerful engineering technology is already being used to edit human embryos, curing diseases and repairing defective genes before a child is even born. Some welcome this new science as a powerful tool to enhance human intelligence, memory, appearance and physical health. Why wouldn’t we embrace a science that allows people to live longer, healthier, and happier lives? Others warn that this new technology will be used to create designer babies and a new class of genetically “enhanced” elites. It will undermine human dignity and autonomy, and risk unleashing new diseases into the human gene pool. Playing G-d with human nature, critics argue, will result in a dystopian nightmare of our own making.

About the Debaters:
Arguing in favour of the motion was the biophysicist, best-selling author, biotechnology entrepreneur, and the former director of the Program on Medicine, Technology and Society at UCLA School of Medicine, Gregory Stock. His debate partner was the internationally acclaimed strategic philosopher and pioneering transhumanist Max More. Arguing against the motion was the prominent American bioethicist Ezekiel Emanuel, Special Advisor to the Director General of the WHO and a former founding chair of the Department of Bioethics at the NIH. His debate partner was the award-winning educator, author, and Professor of Reproductive Science at University College London, Joyce Harper.

Genetically modified hookworms produce and deliver therapeutics

Hookworms, intestinal parasites that infect hundreds of millions of people in under-resourced tropical regions around the globe, have evolved to survive inside the human gut for years, secreting molecules that enable coexistence with their hosts. Now, researchers at Washington University School of Medicine in St. Louis have harnessed that biological mechanism for potential human benefit, engineering a hookworm to produce and deliver a drug within a living host.

In a new study, the team reports the first successful genetic modification of the human hookworm. It was designed to produce an antibody that neutralizes tetrodotoxin, a deadly neurotoxin produced by pufferfish and other marine animals. After colonizing an animal host with the modified hookworms, the parasites produced the antitoxin and secreted it into the bloodstream, partially inactivating the toxin. The findings are published in Nature Communications.

The work demonstrates that this drug production and delivery approach could be a long-term solution to any number of medical needs, from chronic conditions requiring continuous drug treatment to exposure to toxins in remote locations without medical care available.

A new origin story for multicellular life points to physics, not genes alone

How did life make the leap from single cells to coordinated, multicellular organisms? And how do genetically identical cells still perform a version of that feat every time an embryo begins to take shape?

In a new Perspective paper appearing in the journal Nature Biotechnology, Bren Professor of Biology and Biological Engineering Magdalena Zernicka-Goetz and collaborator Qi Chen of the University of Utah ask one of biology’s oldest questions in a new way. The paper is titled “Decoding the origins of cellular self-organization for engineered biology.”

/* */